Sorafenib Tosylate/Comekibart

甲苯磺酸索拉非尼/柯美奇拜单抗

Report date: 2025/10/31 09:47:03

Base Information

Drug NameSorafenib Tosylate/Comekibart
Drug Alias NameSorafenib/MG-K10MG-D-1609
ClassificationBiologics
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsSerine/threonine-protein kinase B-raf inhibitorsVascular endothelial growth factor receptor 1 antagonists +[10] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[10] 
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsYes Sorafenib TosylateComekibart
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMetagone Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesMetagone Biotech Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A